ViGenCell, a leading biotechnology firm, is set to make history by delivering an official oral presentation at the prestigious American Society of Clinical Oncology (ASCO) annual meeting next month. This marks a significant milestone as ViGenCell becomes the first Korean company to present clinical study results for a cell therapy at this esteemed global oncology conference.
The company confirmed that Dr. Jeon Young-woo, the principal researcher for the study, will present the compelling results from their Phase 2 clinical investigation of VT-EBV-N. The presentation will take place during the 2026 ASCO annual meeting, scheduled from May 29 to June 2 in Chicago, drawing oncologists and researchers worldwide.
VT-EBV-N is an innovative Epstein-Barr virus-specific T cell therapy, specifically engineered for the treatment of NK/T-cell lymphoma. This disease is known as a rare and highly aggressive malignancy, frequently associated with a high risk of relapse, making effective new treatments critically important.
ViGenCell’s Phase 2 study of VT-EBV-N has demonstrated highly encouraging and clinically meaningful outcomes. These include a notable reduction in the risks of relapse and a significant improvement in patient survival duration. Comprehensive and detailed data will be unveiled during the official presentation session at the upcoming ASCO event.
The ASCO annual meeting stands as one of the largest and most influential oncology conferences globally, attracting tens of thousands of professionals. While thousands of groundbreaking studies are submitted annually, only a select few are chosen for the highly coveted official oral presentation, underscoring the significance of ViGenCell’s achievement.
“Being selected for an oral presentation at ASCO powerfully highlights the robust clinical strength and accelerating momentum of our cutting-edge program,” stated Ki Pyung-suk, CEO of ViGenCell. “We are eagerly anticipating the opportunity to share the full, comprehensive data with the international oncology community, further propelling our global development and strategic partnering endeavors.”
hwkan
